Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response-Reference-Cited by-同舟云学术

Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response

Published:2018-09-19 Issue:3 Volume:60 Page:852-855
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Babushok Daria V.¹²,Nelson Ernest J.³,Morrissette Jennifer J. D.³,Joshi Shivam⁴,Palmer Matthew B.³,Frank Dale³,Cambor Carolyn L.³,Hexner Elizabeth O.¹

Affiliation:

1. Department of Medicine, Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; USA;

2. Department of Pediatrics, Comprehensive Bone Marrow Failure Center, Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA;

3. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

4. Department of Medicine, Division of Nephrology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Funder

NHLBI

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1509319

Reference14 articles.

1. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis